SCHEMBL1138679

SCHEMBL1138679

Nc1nc(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)cc1CCO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
MTOR P42345 2/20 0.59
ALDH1A1 P00352 2/20 0.59
DNMT1 P26358 2/20 0.59
TP53 P04637 2/20 0.59
THRB P10828 1/20 0.59
MDM2 Q00987 1/20 0.59
NCOA1 Q15788 1/20 0.59
NCOA3 Q9Y6Q9 1/20 0.59
GMNN O75496 1/20 0.59
NFKB1 P19838 1/20 0.59
THPO P40225 1/20 0.59
HTT P42858 1/20 0.59
RAB9A P51151 1/20 0.59
BLM P54132 1/20 0.59
HBB P68871 1/20 0.59
PMP22 Q01453 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1138683 1.00 LMNA (0.59) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL11316774 0.92 LMNA (0.56) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL11325017 0.92 LMNA (0.56) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL11316762 0.92 LMNA (0.56) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL6829082 0.92 LMNA (0.58) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL6241747 0.91 LMNA (0.57) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL2584659 0.91 LMNA (0.57) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL29073820 0.91 LMNA (0.57) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL9856439 0.90 LMNA (0.62) LMNAMTORALDH1A1DNMT1TP53
SCHEMBL18858919 0.90 LMNA (0.62) LMNAMTORALDH1A1DNMT1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12357664-B2 Optimized oncolytic viruses and uses thereof SATOR THERAPEUTICS (US) 2025-07-15 US claimed
EP-4023233-A2 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF Sator Therapeutics LLC (US) 2022-07-06 EP claimed
US-20220088097-A1 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF SATOR THERAPEUTICS 2022-03-24 US claimed
EP-3518947-A1 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF Sator Therapeutics LLC (US) 2019-08-07 EP claimed
WO-2018064134-A1 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF Sator Therapeutics LLC (US) 2018-04-05 WO claimed
US-20180085411-A1 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF SATOR THERAPEUTICS 2018-03-29 US claimed
EP-0948256-A4 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA UNIV WASHINGTON (US) 2007-10-24 EP claimed
US-20050187180-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA UNIVERSITY OF WASHINGTON (US) 2005-08-25 US claimed
US-6887707-B2 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA UNIVERSITY OF WASHINGTON (US) 2005-05-03 US claimed
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-26 US claimed
US-6063628-A Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA UNIVERSITY OF WASHINGTON (US) 2000-05-16 US claimed
EP-0948256-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1999-10-13 EP claimed
WO-1998018324-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1998-05-07 WO claimed
US-12521424-B2 Optimized oncolytic viruses and uses thereof SATOR THERAPEUTICS (US) 2026-01-13 US disclosed
EP-4023233-B1 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF Sator Therapeutics LLC (US) 2026-01-07 EP disclosed
US-12357664-B2 Optimized oncolytic viruses and uses thereof SATOR THERAPEUTICS (US) 2025-07-15 US disclosed
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-26 US disclosed
US-6063628-A Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA UNIVERSITY OF WASHINGTON (US) 2000-05-16 US disclosed
EP-0948256-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1999-10-13 EP disclosed
WO-1998018324-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1998-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA SAMHD1, BCDIN3D, DCTD LMNA 3576/4885MTOR 2746/4885ALDH1A1 1365/4885
US-20050187180-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA SAMHD1, BCDIN3D, DCTD LMNA 3576/4885MTOR 2746/4885ALDH1A1 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.